Intellia Therapeutics Downgraded Amid Safety Concerns and Regulatory Delays
ByAinvest
Tuesday, Nov 25, 2025 8:41 am ET1min read
NTLA--
Intellia Therapeutics (NTLA) has been downgraded by Jones Trading from Buy to Hold due to safety concerns and regulatory delays slowing gene-editing progress. The FDA has placed a hold on NTLA-2001 treatment, and Baird has lowered its price target to $9 while maintaining a Neutral rating. Intellia is a biotech company developing treatments for transthyretin amyloidosis using CRISPR-Cas9 gene-editing technology.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet